Xilio Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A new dual-targeted PSMA/STEAP1 cell engager with CD3 masking and CD2 co-stimulation was announced, aiming to address tumor heterogeneity and resistance in prostate cancer. INDs for this and the claudin 18.2 program are planned for 2027. The CTLA-4 and PD-1 IL-2 programs also showed promising progress.
Fiscal Year 2025
-
Phase II data show Vilastobart plus Atezolizumab yields a 40% response rate in high plasma TMB MSS CRC, with strong safety and biomarker-driven patient selection. Plasma TMB testing is practical and may expand to other cancers, while additional pipeline advances and milestones are expected in 2026.
-
Tumor-activated masking technology is enabling safer, more effective therapies for solid tumors, with promising early results in MSS colorectal cancer and a robust pipeline of bispecific and trispecific cell engagers. Multiple pharma collaborations and key data readouts are expected mid-year.
-
Announced three new masked T-cell engager programs for solid tumors and a major collaboration with AbbVie, including $52M upfront and up to $2.1B in milestones. Preclinical data show strong efficacy and safety for both ATACR and SEECR formats, supporting further development.
-
Initial phase 2 data for vilastobart plus atezolizumab in MSS-CRC show a 27% response rate in patients without liver metastases, rapid and deepening tumor reductions, and a favorable safety profile. No confirmed responses in liver metastases yet, but biomarker declines suggest possible delayed benefit.
Fiscal Year 2024
-
Initial phase I-C data for tumor-activated Vilastobart plus atezolizumab in advanced solid tumors, including MSS-CRC with liver metastases, show encouraging early anti-tumor activity and a differentiated safety profile, supporting ongoing phase II development.
-
The GPS platform enables tumor-selective immunotherapy activation, with XTX101 and XTX301 advancing in clinical trials for MSS CRC and solid tumors, respectively. Key data from phase II and I studies, as well as new multifunctional and cell engager platforms, are expected in Q4, supported by a strong cash position and strategic partnerships.